Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 113-120

  Oliveras Ferraros, Cristina ^a,b   Vazquez Martin, Alejandro ^a,b   Colomer, Ramon ^a,b,c   De Llorens, Rafael ^d   Brunet, Joan ^a,b   Menendez, Javier A ^a,b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b Division of Catalonia   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d UNIVERSITY OF GIRONA   (Spain)

Author keywords

Bcl 2; Breast cancer; Chemotherapy; Gemcitabine; Paclitaxel

Indexed keywords

GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; DRUG ANTAGONISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MATHEMATICAL ANALYSIS; MITOCHONDRIAL RESPIRATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; WESTERN BLOTTING;

EID: 38749145104     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.113     Document Type: Article

References (35)

1. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
2. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156, 1999.
3. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
4. Sawaki M, Ito Y, Hashimoto D, Mizunuma N, Takahashi S, Horikoshi N, Tada K, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A and Hatake K: Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 90: 36-39, 2004.
5. Baltali E, Altundag K, Ozisik Y, Guler N and Tekuzman G: Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. Tohoku J Exp Med 203: 205-210, 2004.
6. Ranson M and Thatcher N: Paclitaxel: a hope for advanced non-small cell lung cancer? Expert Opin Investig Drugs 8: 837-848, 1999.
7. Thomas H and Rosenberg P: Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit Rev Oncol Hematol 44 (suppl): S43-S51, 2002.
8. Hui YF and Reitz J: Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54: 162-170, 1997.
9. Plunkett W, Huang P, Searcy CE and Gandhi V: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23 (suppl 10): 3-15, 1996.
10. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
11. Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG and Possinger K: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10: 625-631, 1999.
12. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J and Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62: 2-8, 2002.
13. Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L and Pouillart P: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60: 303-307, 2001.
14. Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E and Zielinski CC: Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9: 338-342, 2000.
15. Colomer R: What is the best schedule for administration of gemcitabine-taxane? Cancer Treat Rev 31 (suppl 4): S23-S28, 2005.
16. Allouache D, Gawande SR, Tubiana-Hulin M, Tubiana-Mathieu N, Piperno-Neumann S, Mefti F, Bozec L and Genot JY: First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study. BMC Cancer 5: 151, 2005.
17. Yardley DA: Gemcitabine plus paclitaxel in breast cancer. Semin Oncol 32 (suppl 6): S14-S21, 2005.
18. Tomao S, Romiti A, Tomao F, Di Seri M, Caprio G, Spinelli GP, Terzoli E and Frati L: A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. BMC Cancer 6: 137, 2006.
19. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
20. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1989.
21. Chou T-C, Motzer RJ, Tong T and Bosl GJ: Computerized quantitation of synergism and antagonism of paclitaxel, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994.
22. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976-3985, 1993.
23. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-357, 1994.
24. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273: 33533-33539, 1998.
25. Shah GM, Kaufmann SH and Poirier GG: Detection of poly(ADP-ribose) polymerase and its apoptosis-specific fragment by a nonisotopic activity-Western blot technique. Anal Biochem 232: 251-254, 1995.
26. Cory S, Huang DC and Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607, 2003.
27. Chan SL and Yu VC: Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 31: 119-128, 2004.
28. Cory S and Adams JM: Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8: 5-6, 2005.
29. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007.
30. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen C J, Postmus PE, Pinedo HM and Peters GJ: Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17: 2190-2197, 1999.
31. Henley D, Isbill M, Fernando R, Foster JS and Wimalasena J: Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer Chemother Pharmacol 59: 235-249, 2007.
32. Zupi G, Scarsella M, D'Angelo C, Biroccio A, Paoletti G, Lopez M and Leonetti C: Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther 4: 866-871, 2005.
33. Sui M, Xiong X, Kraft AS and Fan W: Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther 5: 1015-1021, 2006.
34. Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Caranana V, Fernandez Y, Garcia-Conde J, Alonso S, Montero S, Hornedo J and Guillem V: Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 15: 201-206, 2004.
35. Colomer R: Gemcitabine and paclitaxel in metastatic breast cancer: a review. Oncology 18 (suppl 12): 8-12, 2004.